Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Medulloblastoma × Lomustine × Clear all

Phase

Phase 3 2 Phase 2 2 Phase NA 1 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Neoplasms 2 Recurrence 1 Neuroectodermal Tumors 1 Medulloblastoma 1 Brain Neoplasms 1

Interventions

Temozolomide 6 Radiotherapy 3 Irinotecan 3 Nivolumab 2 sodium thiosulfate 1 silmitasertib 1 poly ICLC 1 plerixafor 1 lutetium Lu 177 dotatate 1 entrectinib 1 dinutuximab 1 bempegaldesleukin 1 adavosertib 1 abemaciclib 1 Vincristine 1 Vascular Endothelial Growth Factor A 1 Vaccines 1 Triiodothyronine 1 Surgical Procedures, Operative 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1 Melphalan 1 Mannitol 1 Maintenance Chemotherapy 1 Magnetic Resonance Spectroscopy 1 Lomustine 1 Lapatinib 1 HhAntag691 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡